Drug intelligence / Profile preview

RJ007

Development stage: Preclinical
Lead developer: Risen Medical Technology
Modality: Small Molecules

Overview

RJ007 is a preclinical-stage small molecule being developed by Risen Shanghai Medical Technology (Risen Pharma) for the treatment of cancer. As of early 2024, the specific molecular target of RJ007 remains undisclosed by the developer. The drug is part of Risen Pharma's early-stage oncology pipeline, which utilizes small molecule and PROTAC platforms to address various malignancies. It is currently undergoing preclinical research and development to support future clinical applications.

Beyond the preview

Go deeper on RJ007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJ007.

Explore the full profile